SparingVision Reaches Final Dose Escalation Step in PRODYGY Trial with SPVN06 for retinitis pigmentosa
24 janv. 2024 07h00 HE
|
SparingVision
SparingVision Reaches Final Dose Escalation Step in PRODYGY Trial with SPVN06 for retinitis pigmentosa Positive recommendation received from the Data Safety Monitoring Board (DSMB) enabling...
SparingVision Reports Positive Initial Safety Data from the first cohort treated in its PRODYGY Phase I/II Gene Therapy Trial
30 août 2023 07h00 HE
|
SparingVision
SparingVision Reports Positive Initial Safety Data from the first cohort treated in its PRODYGY Phase I/II Gene Therapy Trial Lead gene therapy asset, SPVN06, reported to be well-tolerated in first...
SparingVision sells ex vivo GIRK technology to Tenpoint Therapeutics
12 juil. 2023 07h00 HE
|
SparingVision
SparingVision sells ex vivo GIRK technology to Tenpoint Therapeutics SparingVision remains focused on in vivo genomic medicines, with SPVN20, a GIRK-based gene therapy candidate, expected to reach...
SparingVision Strengthens Leadership Team with the Appointment of Dr Mehdi Gasmi as Chief Operating Officer
09 déc. 2021 07h00 HE
|
SparingVision
SparingVision Strengthens Leadership Team with the Appointment of Dr Mehdi Gasmi as Chief Operating Officer Raffaella Toso, PhD, joins as VP Corporate Development & Alliance Management and...
SparingVision Announces Upcoming Presentations at the Association for Research in Vision and Ophthalmology (ARVO) 2021 Annual Meeting
19 mars 2021 08h00 HE
|
SparingVision
SparingVision Announces Upcoming Presentations at the Association for Research in Vision and Ophthalmology (ARVO) 2021 Annual Meeting Paris, March 19, 2021 – SparingVision (“the Company”), a genomic...
SparingVision Announces Upcoming Presentations at the Association for Research in Vision and Ophthalmology (ARVO) 2021 Annual Meeting
19 mars 2021 02h00 HE
|
SparingVision
SparingVision Announces Upcoming Presentations at the Association for Research in Vision and Ophthalmology (ARVO) 2021 Annual Meeting Paris, March 19, 2021 – SparingVision (“the Company”), a genomic...
Renowned Pioneers in Ophthalmology Join SparingVision’s Scientific Advisory Board
29 janv. 2021 07h00 HE
|
SparingVision
Renowned Pioneers in Ophthalmology Join SparingVision’s Scientific Advisory Board Development of lead asset SPVN06 to further benefit from high-level Clinical Advisory Board ...
Renowned Pioneers in Ophthalmology Join SparingVision’s Scientific Advisory Board
29 janv. 2021 01h00 HE
|
SparingVision
Renowned Pioneers in Ophthalmology Join SparingVision’s Scientific Advisory Board Development of lead asset SPVN06 to further benefit from high-level Clinical Advisory Board ...